Skip to main content
VALN
NASDAQ Life Sciences

Valneva Reports Wider Q1 Loss, Lowers 2026 Guidance Again, and Announces Workforce Reduction

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$5.87
Mkt Cap
$563.202M
52W Low
$5.06
52W High
$12.25
52W Position info
16% above low
Off High info
52% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

VALN sits 16% above its 52-week low of $5.06 on light trading volume (0.3× avg).

Summary

Valneva reported a substantially wider net loss for Q1 2026, further reduced its 2026 revenue guidance, and announced a significant workforce reduction and operating expense cuts to address financial challenges.


Key Events · Earnings and Guidance · VALN

  • Significantly Wider Net Loss in Q1 2026

    Valneva reported a net loss of €32.1 million for the first quarter of 2026, a substantial increase from a €9.2 million net loss in the same period of 2025, primarily due to lower product sales and one-off cost of goods effects.

  • 2026 Guidance Further Lowered

    The company adjusted its 2026 product sales guidance down to €135 million - €150 million (from €145 million - €160 million) and total revenue guidance to €145 million - €160 million, attributing the revision to an adverse trend in travel vaccine uptake.

  • Major Restructuring and Workforce Reduction

    Valneva initiated a restructuring plan to reduce operating expenses by 25-35% in 2026 compared to 2025, which includes a 10-15% reduction in its global workforce.

  • Improved Operating Cash Burn

    Despite the wider net loss, operating cash burn improved significantly to €0.3 million in Q1 2026, compared to €8.1 million in Q1 2025, reflecting diligent cash management.


Analysis · VALN · Life Sciences

Valneva reported a significantly wider net loss for Q1 2026, increasing to €32.1 million from €9.2 million in Q1 2025, driven by lower product sales, declining gross margins, and one-off costs. The company also further lowered its 2026 product sales and total revenue guidance, citing an adverse trend in travel vaccine uptake due to geopolitical factors. In response to these financial pressures, Valneva announced a restructuring plan that includes a 10-15% reduction in its global workforce and a 25-35% cut in 2026 operating expenses. While operating cash burn improved and the company maintains a cash position of €105.3 million (excluding recent financing), the immediate financial performance and outlook are challenging, necessitating significant cost-cutting measures.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VALN was trading at $5.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $563.2M. The 52-week trading range was $5.06 to $12.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VALN - Latest Insights

VALN
Nov 13, 2026, 10:09 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.84
Real-time Price: $5.17 info
Change: -$0.675 (-12%) info
Market Cap: $511.074M info
VALN
Nov 09, 2026, 10:37 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $5.79
Real-time Price: $5.17 info
Change: -$0.625 (-11%) info
Market Cap: $511.074M info
VALN
Oct 07, 2026, 5:41 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $5.61
Real-time Price: $5.17 info
Change: -$0.445 (-8%) info
Market Cap: $511.074M info
VALN
Aug 14, 2026, 11:27 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $7.01
Real-time Price: $5.17 info
Change: -$1.84 (-26%) info
Market Cap: $511.074M info
VALN
Aug 13, 2026, 10:27 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.45
Real-time Price: $5.17 info
Change: -$0.285 (-5%) info
Market Cap: $511.074M info